These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25978924)

  • 1. [Biosimilars: current reality, promising future?].
    Agustí Escasany A; Rodríguez Cumplido D
    Med Clin (Barc); 2015 Jul; 145(1):18-20. PubMed ID: 25978924
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilar medicines: impact, opportunities and strategies. Twelve years of experience in Europe.
    Delgado Sánchez O; Ginard Vicens D; Sampol Mayol A; Terrasa Pons J
    Med Clin (Barc); 2019 May; 152(10):411-415. PubMed ID: 30683321
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 4. Biosimilars for Management of Crohn Disease.
    Nielsen OH; Ainsworth MA
    Ann Intern Med; 2019 Jan; 170(2):129-130. PubMed ID: 30535358
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
    Qureshi ZP; Nagai S; Bennett CL
    JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The importance of biosimilars medicines for private and statutory health insurance].
    Bretthauer B
    Versicherungsmedizin; 2016 Dec; 68(4):173-5. PubMed ID: 29144116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars take center stage.
    Adams KT
    Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533
    [No Abstract]   [Full Text] [Related]  

  • 10. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rise of biosimilars in cancer care.
    Roe H
    Br J Nurs; 2015 Feb 26-Mar 11; 24(4):S28-9. PubMed ID: 25723369
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
    Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: from technical to pharmacoeconomic considerations. 30th Rencontres Nationales de Pharmacologie et Recherche clinique pour l'Innovation et l'Evaluation des Technologies de Santé. Tables rondes.
    Girault D; Trouvin JH; Blachier-Poisson C; Gary F; Laloye D; ; Bergmann JF; Casadevall N; Delval C; De Sahb Berkovitch R; Fagon JY; Gersberg M; Lassale C; Lechat P; Le Jeunne C; Montastruc JL; Prugnaud JL; Ratignier-Carbonneil C; Rey-Coquais C;
    Therapie; 2015; 70(1):37-55. PubMed ID: 25679193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar drugs: Measures to promote their use.
    Guiu Segura JM; Gilabert Perramon A
    Med Clin (Barc); 2020 Feb; 154(4):148. PubMed ID: 30981435
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The brave new world of biosimilars ('similar biologics') in India.
    Jois R
    Postgrad Med J; 2017 Oct; 93(1104):577-579. PubMed ID: 28546231
    [No Abstract]   [Full Text] [Related]  

  • 19. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilars and the efficiency principle].
    Münnch T
    Laryngorhinootologie; 2017 Dec; 96(12):828-830. PubMed ID: 29195262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.